NCT07108270View on ClinicalTrials.gov

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2030

Conditions

Neoplasms, Endometrial

Interventions

BIOLOGICAL

Dostarlimab

Dostarlimab will be administered.

DRUG

Carboplatin

Carboplatin will be administered.

DRUG

Paclitaxel

Paclitaxel will be administered.

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY